Call for Abstracts: 2014 – Exploiting bacteriophages for bioscience, biotechnology and medicine


You can now submit an abstract to the upcoming ‘2014 – Exploiting bacteriophages for bioscience, biotechnology and medicine (the 5th in a biennial series)’ meeting.

  • Deadline for abstracts to be considered for oral presentation: October 10th 2013
  • Deadline for abstracts to be considered for poster presentation: Up to 2 weeks before the event
You can download the instructions for authors at

Please see the following link for more information:

Abstracts can be submitted to:

When: Thursday 23rd January 2014


Cineworld: The O2
Peninsula Square
United Kingdom

What: Bacteriophages (phages) are arguably the most abundant biological entities on the planet. They play crucial roles in driving the adaptive evolution of their bacterial hosts, and achieve this both through the predator)prey roles of the phage)bacterium interaction and through the adaptive impacts of lysogeny and lysogenic conversion.  Bacteriophages are the source of many biochemical reagents and technologies, indispensible for modern molecular biology.  Furthermore, phages are being exploited in other areas of biotechnology, including diagnostics, prophylaxis and other aspects of food microbiology. In recent years there has been a growing interest in developing phages for therapeutic purposes (phage therapy) as natural alternatives to antibiotics. The inexorable rise in the incidence of antibiotic resistance in bacterial pathogens, coupled with the disappointingly low rate of emergence of new, clinically useful antibiotics, has refocused attention on the potential utility of phages for treating human and animal disease. Examples of the roles of phages in fundamental biological research and in medical and industrial biotechnologies will be discussed at this meeting

This event  has CPD accreditation and will have a discussion panel session.

Who: Meeting chair: Professor George Salmond, University of Cambridge, UK


Latest Euroscicon Tweets

Error: You currently have access to a subset of Twitter API v2 endpoints and limited v1.1 endpoints (e.g. media post, oauth) only. If you need access to this endpoint, you may need a different access level. You can learn more here: